Trial · NCT03661541
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A: 6 or More Herpes Labialis Outbreaks, Day 1 | IL5 in negative control | 10.073 | Standard Deviation 0.544 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group B: 1 or 2 Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 in negative control | 11.380 | Standard Deviation 1.233 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group C: Zero Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 in negative control | 10.711 | Standard Deviation 1.274 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A, Day 57. Subjects With 6 or More Outbreaks, 8 Weeks After Single Dose of SADBE. | IL5 in negative control | 11.431 | Standard Deviation 1.143 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A: 6 or More Herpes Labialis Outbreaks, Day 1 | IL5 with HSV-1-infected cell extract stimulus | 9.624 | Standard Deviation 0.666 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group B: 1 or 2 Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with HSV-1-infected cell extract stimulus | 10.983 | Standard Deviation 0.971 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group C: Zero Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with HSV-1-infected cell extract stimulus | 10.986 | Standard Deviation 1.268 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A, Day 57. Subjects With 6 or More Outbreaks, 8 Weeks After Single Dose of SADBE. | IL5 with HSV-1-infected cell extract stimulus | 10.627 | Standard Deviation 0.810 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A: 6 or More Herpes Labialis Outbreaks, Day 1 | IL5 with HSV-1 virus stimulus | 9.747 | Standard Deviation 0.697 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group B: 1 or 2 Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with HSV-1 virus stimulus | 10.736 | Standard Deviation 0.880 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group C: Zero Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with HSV-1 virus stimulus | 10.414 | Standard Deviation 1.217 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A, Day 57. Subjects With 6 or More Outbreaks, 8 Weeks After Single Dose of SADBE. | IL5 with HSV-1 virus stimulus | 10.595 | Standard Deviation 0.957 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A: 6 or More Herpes Labialis Outbreaks, Day 1 | IL5 with Candida stimulus | 10.680 | Standard Deviation 0.941 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group B: 1 or 2 Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with Candida stimulus | 10.806 | Standard Deviation 1.093 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group C: Zero Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IL5 with Candida stimulus | 11.051 | Standard Deviation 1.332 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A, Day 57. Subjects With 6 or More Outbreaks, 8 Weeks After Single Dose of SADBE. | IL5 with Candida stimulus | 10.536 | Standard Deviation 1.215 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A: 6 or More Herpes Labialis Outbreaks, Day 1 | IFNG in negative control | 10.033 | Standard Deviation 0.820 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group B: 1 or 2 Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IFNG in negative control | 10.210 | Standard Deviation 1.320 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group C: Zero Herpes Labialis Outbreaks in Prior 12 Months, Day 1 | IFNG in negative control | 9.729 | Standard Deviation 1.902 | q-RT-PCR crossing threshold cycle (Ct) |
| Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline | Group A, Day 57. Subjects With 6 or More Outbreaks, 8 Weeks After Single Dose of SADBE. | IFNG in negative control | 9.718 | Standard Deviation 1.164 | q-RT-PCR crossing threshold cycle (Ct) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03661541/results